Company profile
NuCana plc
NASDAQ:NCNABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FOSGEMCITABINE PALABENAMIDE | phase3 | — | 2 | terminated |
| Fosdesdenosine Sipalabenamide | phase1_2 | — | 1 | active |
| fosifloxuridine nafalbenamide | phase1_2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03829254 | phase1_2 | recruiting | 2019-06-17 | 2026-08-01 | NuCana plc | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma |
| NCT03428958 | phase1_2 | completed | 2018-10-05 | 2024-03-19 | NuCana plc | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment |
| NCT05678257 | phase2 | terminated | 2023-04-18 | 2024-08-29 | NuCana plc | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer |
| NCT04163900 | phase3 | terminated | 2019-12-24 | 2022-03-02 | NuCana plc | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer |
| NCT03146663 | phase2 | terminated | 2017-09-28 | 2019-12-31 | NuCana plc | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer |
FDA applications (0)
No records yet.